Core--Xenograft Facility

核心--异种移植设施

• 批准号: 6844503
• 负责人: Charles David James
• 金额: $ 16.36万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-10-01 至 2009-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6844503
• 关键词: athymic mouse; biomedical facility; glioma; human tissue; neoplasm /cancer transplantation; nuclear magnetic resonance spectroscopy; tissue resource /registry

Through the development and maintenance of several serially transplantable GBM tumor lines, each of which has been or will be characterized for GBM signature lesions, the Xenograft Core will provide to SPORE investigators robust animal models that recapitulate the invasiveness seen in the human phenotype. The serially passaged xenografts provide a more clinically relevant model than established cell lines grown as xenografts. This determination has many implications for neuro-oncology research, but is likely to be of greatest importance to the testing of experimental therapeutics. It is our contention that results from testing anti-tumor therapeutics with serially-transplanted GBM xenografts will show improved consistency with clinical trial results in humans. Specifically, the Xenograft Core will: 1: Initiate, passage, and archive xenograft tumors derived from Mayo glioma patients. 2: Provide detailed molecular characterization of each xenograft upon establishment and monitor for retention of characteristics. 3: Collect, process, and distribute within and outside Mayo, paraffin-embedded xenograft tumor tissues, serum/plasma, DNA, RNA, and protein. 4: Coordinate and conduct all in vivo therapeutics testing, including NMR image analysis of intracranial xenografts as needed to assess tumor response to therapy. 5: Maintain up-to-date records on all xenograft tissues and related biospecimens. All specimens will be collected and processed under tight quality control, and will be distributed to SPORE researchers or banked for future SPORE research projects. The SPORE Pathology Core will assure that specimens are properly fixed, stained, and histologically evaluated. All activities will be tracked in the Biostatistics Core using a sophisticated database essential to the SPORE. This database merges the activities at Mayo, and allows integration with clinical and other data collected in research projects.

通过开发和维持几种串行移植的GBM肿瘤系，每种肿瘤系已或将是GBM签名病变的特征，异种移植物核心将为孢子研究者提供强有力的动物模型，这些动物模型概述了人类表型中看到的侵入性。串行的异种移植物提供了比作为异种移植物生长的已建立的细胞系更临床相关的模型。这种确定对神经肿瘤研究具有许多影响，但对于测试实验疗法可能最重要。我们的论点是，通过串行转移的GBM异种移植物测试抗肿瘤治疗剂的结果将显示出与人类临床试验结果的一致性的改善。 具体而言，异种移植核心将： 1：启动，通道和档案异种移植肿瘤，这些肿瘤来自蛋黄酱患者。 2：在建立时提供每个异种移植物的详细分子表征，并监控保留特征。 3：收集，加工和分布在蛋黄酱内外，石蜡膜的异种移植肿瘤组织，血清/血浆，DNA，RNA和蛋白质。 4：协调和进行所有体内治疗学测试，包括根据需要评估肿瘤对治疗反应的颅内异种移植物的NMR图像分析。 5：在所有异种移植组织和相关的生物测量中保持最新记录。 所有标本都将在严格的质量控制下收集和处理，并将分发给孢子研究人员或用于未来的孢子研究项目。孢子病理核心将确保标本正确固定，染色和组织学评估。所有活动将使用孢子必不可少的复杂数据库在生物统计学核心中进行跟踪。该数据库合并了Mayo的活动，并允许与研究项目中收集的临床和其他数据集成。